Preparation process for XPO1 inhibitors and intermediates used in the preparation of XPO1 inhibitors

Abstract

To provide a process for preparing an XPO1 inhibitor and an intermediate used in the preparation thereof.SOLUTION: Provided is a process comprising a step of generating an intermediate compound of formula III, as illustrated in the reaction scheme below, and then reacting the intermediate compound with a specific hydrazine to produce the compound of formula VII.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Related applications This application claims the benefits of U.S. Provisional Patent Application No. 62 / 841,649, filed on 1 May 2019. All teachings relating to the said application are incorporated herein by reference.

[0002] The present invention relates to a preparation process for XPO1 inhibitors and intermediates used in the preparation of XPO1 inhibitors. [Background technology]

[0003] Selinexol is a selective inhibitor of nuclear export used to treat and / or prevent physiological conditions associated with CRM1 / XPO1 activity. Selinexol has the following structural formula: [ka] It is represented by [this].

[0004] The synthesis of selinexol was first disclosed in Patent Document 1 by Karyopharm Therapeutics Inc. While the synthesis method reported there was successful in providing small quantities of selinexol, they struggled with the need for multiple purification steps (chromatography and crystallization) to obtain selinexol with the desired high Z-isomer content. Although the process disclosed in this application was well-suited for the scale they intended, these purification steps made it inefficient for commercial production.

[0005] An improved synthesis of selinexol from the second-to-last intermediate (represented by structural formula III below) is disclosed in Patent Document 2, also by Karyopharm Therapeutics Inc. Although the challenges related to the final synthetic step of converting intermediate III to selinexol have been resolved, a method for preparing intermediate III is not provided. [Prior art documents] [Patent Documents]

[0006] [Patent Document 1] International Publication No. 2013019548A1 Pamphlet [Patent Document 2] International Publication No. 2016025904A1 Pamphlet [Overview of the Initiative] [Problems that the invention aims to solve]

[0007] There is a need for efficient manufacturing processes suitable for the preparation of selinexol and its intermediates on a commercially appropriate scale.

[0008] The present invention aims to provide novel and efficient processes for preparing intermediates (e.g., compounds represented by structural formula III) useful in the synthesis of selinexol. These processes solve the challenges associated with the presynthesis of selinexol. [Means for solving the problem]

[0009] This invention relates to the structural formula III [ka] A process that forms a compound represented by: Compound represented by structural formula (I) and compound represented by structural formula (II) [ka] The compound represented by structural formula (IIIa) is obtained in the presence of a catalyst, an organic base, and an ether-containing solvent. [ka] A step of reacting under conditions suitable for the production of; and A step of reacting a compound represented by structural formula (IIIa) with an inorganic base in the presence of isopropyl alcohol (IPA) under conditions suitable for the formation of the compound represented by structural formula (III) without isolation; and including a step of isolating the compound represented by structural formula (III), where R is C2-C5 alkyl, C6-C 18 aryl, 5-18 member heteroaryl, C3-C 12 cycloalkyl or 3-12 member heterocycloalkyl, each of which is optionally and independently substituted with one or more substituents selected from halo, CN, OH, C1-C3 alkyl, C1-C3 haloalkyl, -NO2, -NH2, -NH(C1-C3 alkyl), -N(C1-C3 alkyl)2 and C1-C3 alkoxy, relating to a process.

[0010] As described in the following examples herein, by adopting a combination of a catalyst, an organic base, an ether-containing solvent, an inorganic base and a phase transfer catalyst in the method for synthesizing the compound represented by structural formula III, unexpectedly high yields and excellent stereoselectivity were obtained while eliminating the step of isolating the intermediate.

[0011] The foregoing will become apparent from the following more specific description of exemplary embodiments of the invention as illustrated in the accompanying drawings, wherein like reference numerals refer to the same components throughout the different figures. The drawings are not necessarily to scale and emphasis has been made in the illustration of embodiments of the invention.

[0012] That is, the gist of the present invention relates to the following. Item 1 A compound represented by structural formula VII

Chemical formula

[0013] The present invention may provide a process for preparing an XPO1 inhibitor and intermediates used in the preparation of an XPO1 inhibitor. [Brief explanation of the drawing]

[0014] [Figure 1] Figure 1 shows the powder X-ray diffraction (XRPD) pattern of selinexol morph A as described in U.S. Patent No. 10,519,139. [Figure 2]Figure 2 shows the XRPD pattern of the acetonitrile solvate of selinexol as described in U.S. Patent No. 10,519,139. [Modes for carrying out the invention]

[0015] The novel mechanism according to the present invention will become apparent to those skilled in the art through the following consideration of embodiments for carrying out the invention. However, it should be understood that while the embodiments and specific examples presented represent certain embodiments of the invention, various changes and modifications within the spirit and scope of the invention are provided for illustrative purposes only, as they will become apparent to those skilled in the art from the following embodiments and claims for carrying out the invention.

[0016] definition The compounds of the present invention broadly include those described above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, unless otherwise specified, the following definitions apply. For the purposes of the present invention, chemical elements are defined in Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th The general principles of organic chemistry are identified according to the ed. Furthermore, the general principles of organic chemistry are found in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5 th This is described in Ed., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001, and its entire contents are incorporated herein by reference.

[0017] Unless otherwise specified herein, the nomenclature used herein generally follows the examples and rules set forth in *Nomenclature of Organic Chemistry*, Sections A, B, C, D, E, F, and H, Pergamon Press, Oxford, 1979 (exemplary chemical structure names and rules for chemical structure nomenclature are incorporated herein by reference). Optionally, compound names may be generated using the chemical naming program: ACD / ChemSketch, Version 5.09 / September 2001, Advanced Chemistry Development, Inc., Toronto, Canada.

[0018] "Alkyl" means, for example, a saturated aliphatic branched or linear monovalent hydrocarbon group having 1 to 16 carbon atoms. For example, "(C1-C6) alkyl" means a group having 1 to 6 carbon atoms arranged in a linear or branched chain. "(C1-C6) alkyl" includes methyl, ethyl, propyl, butyl, pentyl, and hexyl. In one embodiment, the alkyl group contains 2 to 5 carbon atoms.

[0019] As defined above, "alkane" refers to a hydrocarbon molecule consisting of alkyl groups bonded to hydrogen.

[0020] "Cycloalkyl" refers to a saturated aliphatic cyclic hydrocarbon group having, for example, 3 to 12 carbon atoms. This can be monocyclic or polycyclic (e.g., condensed, cross-linked, or spiro). For example, a monocyclic (C3-C8) cycloalkyl refers to a group having 3 to 8 carbon atoms arranged on a monocyclic ring. Examples of monocyclic (C3-C8) cycloalkyls are not particularly limited, but include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctane.

[0021] As defined above, "cycloalkane" refers to a hydrocarbon molecule consisting of a cycloalkyl group bonded to a hydrogen atom.

[0022] "Hypercycloalkyl" refers to a saturated ring having, for example, 3 to 12 members, containing a carbon atom and 1 to 4 heteroatoms, which may be the same or different, selected from N, O, or S, and optionally containing one or more double bonds. This can be monocyclic or polycyclic (e.g., condensed, bridging, or spiro).

[0023] "Haloalkyl" refers to a linear or branched alkyl group as defined above, where some or all of the hydrogen atoms may be substituted with halogen atoms, and may also include mono, poly, and perhaloalkyl groups, where the halogen is independently selected from fluorine, chlorine, and bromine.

[0024] "Heteroaryl" refers to a monovalent aromatic heterocyclic, monocyclic, or polycyclic ring group. Heteroaryl rings can have 5 to 18 members and can contain a carbon atom and 1 to 4 heteroatoms independently selected from N, O, and S. They can be monocyclic or polycyclic, but are not limited to these, including furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, 1,3,4-oxadiazole, 1,2,5-thiadiazole, 1,2,5-thiadiazole 1-oxide, 1,2,5-thiadiazole 1,1-dioxide, and 1,3,4-thiadiazole Examples include ru, pyridine, pyridine-N-oxide, pyrazine, pyrimidine, pyridazine, 1,2,4-triazine, 1,3,5-triazine, tetrazole, indidine, indole, isoindole, benzo[b]furan, benzo[b]thiophene, indazole, benzimidazole, benzthiazole, purine, 4H-quinolidine, quinoline, isoquinoline, cinoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine.

[0025] "Alkoxy" refers to the alkyl group defined above, which is bonded via an oxygen-bonding atom. Examples of "(C1~C3)-alkoxy" include methoxy, ethoxy, propoxy, and isopropoxy.

[0026] "Aryl" refers to, for example, an aromatic monocyclic or polycyclic hydrocarbon ring system containing 6 to 18 carbon members. Examples of aryl systems, though not particularly limited, include phenyl, naphthalenyl, fluorenyl, indenyl, azlenyl, and anthracenyl.

[0027] "Arene" refers to a hydrocarbon molecule consisting of an aryl group bonded to a hydrogen atom.

[0028] The definition of a group as defined above also includes groups that are optionally substituted with a carbon or nitrogen atom, to the extent permitted by valence. Preferred substitutions, but are not limited to, include halo, CN, OH, C1-C3 alkyl, C1-C3 haloalkyl, -NO2, -NH2, -NH(C1-C3 alkyl), -N(C1-C3 alkyl)2, and C1-C3 alkoxy.

[0029] As used herein, "halo" refers to fluorine, chlorine, bromine, or iodine.

[0030] As used herein, the term "hydrocarbon solvent" means an alkane, cycloalkane, or arene having 5 to 12 carbon atoms.

[0031] "Catalyst" means any compound that can be modified by particularly increasing the rate of the chemical reaction involved and that is regenerated at the end of the reaction. Examples of catalysts suitable for this application, but not limited to these, include 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undeca-7-ene (DBU), and 7-methyl-1,5,7-triazabicyclo[4.4.0]deca-5-ene (MTBD), 1,5,7-triazabicyclo[4.4.0]deca-5-ene (TBD), and quinuclidine.

[0032] As used herein, "organic base" refers to an organic compound capable of accepting a proton, forming a hydroxyl ion in aqueous solution, or donating an electron pair. Examples of organic bases, but not limited to these, include nitrogen-containing compounds such as Et3N, diisopropylethylamine (DIPEA), piperidine, pyridine, 4-dimethylaminopyridine (DMAP), N-methylmorpholine, dimethylaniline, imidazole, 1-methylpyridine, 2-methylpyridine, 3-methylpyridine, 3,5-dimethylpyridine, 2,4-dimethylpyridine, 2,6-dimethylpyridine, and 2,4,6-trimethylpyridine.

[0033] As used herein, "inorganic base" refers to an inorganic compound capable of accepting protons, forming hydroxyl groups in an aqueous medium, or donating electron pairs. Examples of inorganic bases, but not limited to these, include metal hydroxides such as LiOH, NaOH, KOH, CsOH, Ca(OH)2, Mg(OH)2, and Ba(OH)2.

[0034] As used herein, "ether-containing solvent" refers to an organic compound that is liquid under ambient conditions and contains an R'-OR'' moiety, where R' and R'' are independently selected from linear, branched, or cycloalkyl groups, and R' and R'' can form a 5- to 6-membered ring together with the oxygen atoms to which they are bonded. Examples of ether-containing solvents, but not limited to these, include 2-methyltetrahydrofuran (MeTHF), diethyl ether, methyl t-butyl ether (MTBE), tetrahydrofuran (THF), 2,5-dimethyltetrahydrofuran (DiMeTHF), dimethoxyethane (DME), and cyclopentyl methyl ether (CPME).

[0035] It is understood that the substituents and substitution patterns in the compounds of the present invention are selectable by those skilled in the art so as to provide compounds that are chemically stable and readily synthesizable by art known in the art and by the methods described below. Generally, the term “substituted” means that one or more hydrogen atoms relating to a specified part are replaced by a suitable substituent, whether preceded by the term “optionally substituted.” Unless otherwise specified, an “optionally substituted group” may have a suitable substituent at each of its substituted positions, and if two or more positions in any given structure can be substituted by two or more substituents selected from a particular group, the substituents may be identical or different at all positions. Alternatively, an “optionally substituted group” may not be substituted at all.

[0036] The combinations of substituents contemplated by the present invention are preferably those that result in the formation of compounds that are stable or chemically feasible. When a substituent itself is substituted by two or more groups, these multiple groups can be on the same carbon atom or on different carbon atoms, as long as the structure formed is stable and chemically feasible. As used herein, the term "stable" refers to a compound that does not substantially change when subjected to the conditions that permit its generation, detection, and in certain embodiments, its recovery, purification, and use, in relation to one or more of the purposes disclosed herein.

[0037] Unless otherwise specified, the structures shown herein also include all isomeric forms related to this structure (e.g., enantiomeric, diastereomeric, and geometric (or conformational) isomeric forms); for example, the R and S configurations related to each chiral center, the Z and E double bond isomers. Thus, single stereochemical isomers of the compounds of the present invention, as well as mixtures of enantiomeric, diastereomeric, and geometric (or conformational) isomers, are within the scope of the present invention. Unless otherwise specified, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.

[0038] Also, unless otherwise specified, the structures shown herein also mean that they include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds generated by replacement of hydrogen with deuterium or tritium, or replacement of carbon with 13C- or 14C-enriched carbon are within the scope of the present invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents according to the present invention. 13 C- or 14 C-enriched carbon are within the scope of the present invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents according to the present invention.

[0039] The term "stereoisomer" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. This term includes enantiomers, geometric (cis / trans) isomers, and diastereomers (isomers of compounds that have two or more non-mirror images of each other's chiral centers).

[0040] In introducing elements disclosed herein, the articles “a,” “an,” “the,” and “said” are intended to indicate the presence of one or more elements. The terms “comprising,” “having,” and “including” are intended to be open-ended and to indicate that additional elements other than those listed may exist.

[0041] Abbreviation aq. Water-based CPME Cyclopentyl Methyl Ether DABCO 1,4-Diazabicyclo[2.2.2]octane DD Distilled, Deionized DIEA N,N-diisopropylethylamine DMF Dimethylformamide EA or HCl (ethyl acetate) Et2O Diethyl ether EtOH Ethanol Et ethyl eq equivalent h time HCl (hydrochloric acid) IPA 2-propanol KOH (Potassium Hydroxide) LCMS Liquid Chromatography / Mass Spectroscopy LiOH (Lithium Hydroxide) MeCN acetonitrile MeOH methanol MTBE methyl t-butyl ether min minutes Me methyl MeTHF 2-methyltetrahydrofuran NaOH (Sodium Hydroxide) NaCl (Sodium Chloride) NMT or less NLT or higher ND (Not Detected) NMR nuclear magnetic resonance org.organic RT, rt, rt room temperature THF (Tetrahydrofuran) Temp Temperature UPLC or UHPLC High-Performance Liquid Chromatography wts weight equivalent

[0042] Method of the present invention In the first embodiment, the present invention relates to a compound represented by structural formula III. [ka] Regarding the process for forming, This process: Compound represented by structural formula (I) and compound represented by structural formula (II) [ka] The compound represented by structural formula (IIIa) is obtained in the presence of a catalyst, an organic base, and an ether-containing solvent. [ka] A step of reacting under conditions suitable for the production of; and A step of reacting a compound represented by structural formula (IIIa) with an inorganic base in the presence of isopropyl alcohol (IPA) under conditions suitable for the formation of a compound represented by structural formula (III), without isolation; and The process includes the step of isolating the compound represented by structural formula (III), Here, R is C2-C5 alkyl, C6-C 18 Aryl, 5-18 member heteroaryl, C3-C 12The molecules are cycloalkyl or 3- to 12-membered heterocycloalkyl, each of which is optionally and independently substituted with one or more substituents selected from halo, CN, OH, C1-C3 alkyl, C1-C3 haloalkyl, -NO2, -NH2, -NH(C1-C3 alkyl), -N(C1-C3 alkyl)2, and C1-C3 alkoxy.

[0043] In the first embodiment of the first embodiment, R is a C2-C5 alkyl or C6-C 18 It is an aryl group. For example, R is a C2-C5 alkyl group, for example, R is isopropyl. Or, R is phenyl.

[0044] In a second embodiment of the first embodiment, the catalyst is present in an amount of 0.05 to 0.2 molar equivalents based on the amount of the compound represented by structural formula I. For example, the catalyst is present in an amount of 0.1 molar equivalents based on the amount of the compound represented by structural formula I. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first aspect of the first embodiment.

[0045] In a third aspect of the first embodiment, the catalyst is selected from the group consisting of 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undeca-7-ene, and 7-methyl-1,5,7-triazabicyclo[4.4.0]deca-5-ene. For example, the catalyst is DABCO. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first and second aspects of the first embodiment.

[0046] In the fourth aspect of the first embodiment, the organic base is present in an amount of 0.5 to 2 molar equivalents based on the amount of the compound represented by structural formula I, for example, the organic base is present in an amount of 1.0 molar equivalent based on the amount of the compound represented by structural formula I. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to third aspects of the first embodiment.

[0047] In the fifth aspect of the first embodiment, the organic base is selected from the group consisting of DIPEA, Et3N, piperidine, pyridine, and 4-(dimethylamino)pyridine, for example, the organic base is DIPEA. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to fourth aspects of the first embodiment.

[0048] In the sixth embodiment of the first embodiment, the ether-containing solvent is selected from the group consisting of MeTHF, CPME, and MTBE. For example, the ether-containing solvent is MeTHF. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to fifth embodiments of the first embodiment.

[0049] In the seventh aspect of the first embodiment, the compound of structural formula II is present in an amount of 1.0 to 1.5 molar equivalents based on the amount of the compound of structural formula I. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixth aspects of the first embodiment.

[0050] In the eighth aspect of the first embodiment, the inorganic base is KOH or NaOH. For example, the inorganic base is KOH. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to seventh aspects of the first embodiment.

[0051] In the ninth aspect of the first embodiment, the present invention relates to a process in which conditions suitable for producing the compound represented by structural formula IIIa are to react the compound represented by structural formula I with the compound represented by structural formula II at temperatures such as about 5°C to about 55°C, about 10°C to about 40°C, or about 10°C to about 30°C (for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30). The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to eighth aspects of the first embodiment.

[0052] In the tenth aspect of the first embodiment, preferred conditions for producing the compound represented by structural formula IIIa include reacting the compound represented by structural formula I with the compound represented by structural formula II for a period of about 5 to about 30 hours, about 10 to about 30 hours, etc. (10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30, etc.). The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to ninth aspects of the first embodiment.

[0053] In the eleventh aspect of the first embodiment, preferred conditions for producing the compound represented by structural formula III include reacting the compound represented by structural formula IIIa with an inorganic base at temperatures such as about 5°C to about 55°C, about 10°C to about 40°C, and about 10°C to about 30°C (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30). The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to tenth aspects of the first embodiment.

[0054] In the twelfth aspect of the first embodiment, preferred conditions for the formation of the compound represented by structural formula III include reaction steps of the compound represented by structural formula IIIa and an inorganic base for a duration of about 1 to 20 hours, about 1 to 10 hours, etc. (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10), about 2 to 4 hours, etc. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to eleventh aspects of the first embodiment.

[0055] In a thirteenth embodiment of the first embodiment, the present invention relates to a process further comprising the step of isolating a compound represented by structural formula III from a reaction mixture. For example, the present invention relates to a step of isolating a compound represented by structural formula III: (i) Add water and HCl to a reaction mixture containing the compound represented by structural formula III, thereby generating an aqueous phase and an organic phase; (ii) Separating the organic phase and, by optional means, concentrating it to produce the final organic phase; (iii) C5~C 12 The steps include adding a hydrocarbon solvent to the final organic phase to produce a precipitate of the compound represented by structural formula III, and (iv) Step of isolating the precipitate of the compound represented by structural formula III. The process includes the following: For example, the precipitate is isolated by centrifugation or filtration. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to twelfth aspects of the first embodiment.

[0056] In the 14th embodiment of the first embodiment, C5~C 12 The hydrocarbon solvent is heptane. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to thirteenth aspects of the first embodiment.

[0057] In the 15th embodiment of the first embodiment, C5~C 12 The hydrocarbon solvent is isooctane. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to thirteenth aspects of the first embodiment.

[0058] In the sixteenth aspect of the first embodiment, the catalyst and the organic base are present in a combined total amount less than one molar equivalent of the compound represented by structural formula II. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to fifteenth aspects of the first embodiment.

[0059] In a second exemplary embodiment, the present invention relates to the first exemplary embodiment and its first to sixteenth aspects relating to the above process, wherein the compound represented by structural formula (IV) [ka] And, hydrazine represented by structural formula (V) H2NNH2(V) and are compounds represented by structural formula (I) [ka] A step of reacting under conditions suitable for the production of; and Steps to isolate the compound represented by structural formula (I) This process further includes the following:

[0060] In the first embodiment of the second exemplary embodiment, the step of reacting the compound represented by structural formula (IV) with the hydrazine represented by structural formula (V) is carried out in the presence of an organic acid, such as formic acid, acetic acid, or propionic acid. In one example, the organic acid is acetic acid. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth embodiments of the first embodiment.

[0061] In the second embodiment of the second exemplary embodiment, preferred conditions for producing the compound represented by structural formula (I) include the step of reacting the compound represented by structural formula (IV) with hydrazine represented by structural formula (V) at a temperature of 50°C to 60°C. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth aspects of the first embodiment and the first aspect of the second exemplary embodiment.

[0062] In a third exemplary embodiment, the present invention relates to the first exemplary embodiment and its first to sixteenth aspects relating to the above process, wherein the compound represented by structural formula (III) [ka] And, hydrazine represented by structural formula (VI) [ka] The compound represented by structural formula (VII) is obtained in the presence of a polar solvent, a second organic base, and a coupling agent. [ka] A step of reacting under conditions suitable for the production of [the substance]; A step of replacing the polar solvent with acetonitrile (ACN); and Steps to crystallize the compound represented by structural formula (VII) from ACN as crystalline form D. This process further includes the following:

[0063] In the first embodiment of the third exemplary embodiment, the second organic base is selected from the group consisting of DIPEA, Et3N, piperidine, pyridine, and 4-(dimethylamino)pyridine. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth aspects of the first embodiment and the first and second aspects of the second exemplary embodiment.

[0064] In the second embodiment of the third exemplary embodiment, the second organic base is DIPEA. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth embodiments of the first embodiment, the first and second embodiments of the second exemplary embodiment, and the first embodiment of the third exemplary embodiment.

[0065] In the third embodiment of the third exemplary embodiment, the polar solvent is selected from the group consisting of C1-C6 alcohols, MeTHF, CPME, and MTBE, for example, MeTHF. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth embodiments of the first embodiment, the first and second embodiments of the second exemplary embodiment, and the first and second embodiments of the third exemplary embodiment.

[0066] In the fourth embodiment of the third exemplary embodiment, the coupling agent is selected from the group consisting of propylphosphonic anhydride (T3P) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). For example, the coupling agent is T3P. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth embodiments of the first embodiment, the first and second embodiments of the second exemplary embodiment, and the first to third embodiments of the third exemplary embodiment.

[0067] In the fifth embodiment of the third exemplary embodiment, preferred conditions for producing the compound represented by structural formula (VII) include the step of reacting the compound represented by structural formula (III) with hydrazine represented by structural formula (VI) at a temperature of -25°C to -15°C. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth embodiments of the first embodiment, the first and second embodiments of the second exemplary embodiment, and the first to fourth embodiments of the third exemplary embodiment.

[0068] In the sixth embodiment of the third exemplary embodiment, the process further includes the step of recrystallizing form D of the compound represented by structural formula (VII) in aqueous isopropyl alcohol (IPA) under conditions suitable for producing crystalline form A of the compound represented by structural formula (VII). The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth embodiments of the first embodiment, the first and second embodiments of the second exemplary embodiment, and the first to fifth embodiments of the third exemplary embodiment.

[0069] In the seventh embodiment of the third exemplary embodiment, preferred conditions for producing form A of the compound represented by structural formula (VII) include: dissolving form D in aqueous IPA to produce a slurry; and holding the slurry at a temperature of 38°C to 42°C for 5 to 12 hours. The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth embodiments of the first embodiment, the first and second embodiments of the second exemplary embodiment, and the first to sixth embodiments of the third exemplary embodiment.

[0070] In a fourth exemplary embodiment, the present invention relates to the first exemplary embodiment and its first to sixteenth aspects relating to the above process, wherein the compound represented by structural formula (IV) [ka] And, hydrazine represented by structural formula (V) H2NNH2(V) and are compounds represented by structural formula (I) [ka] A step of reacting under conditions suitable for the production of [the substance]; A step of isolating the compound represented by structural formula (I); The steps of preparing the compound of formula (III) according to the process described herein (the first embodiment and all aspects thereof), and the compound represented by structural formula (III) [ka] And, hydrazine represented by structural formula (VI) [ka] The compound represented by structural formula (VII) is obtained in the presence of a polar solvent, a second organic base, and a coupling agent. [ka] A step of reacting under conditions suitable for the production of [the substance]; A step of replacing the polar solvent with acetonitrile (ACN); The step further comprises: crystallizing the compound represented by structural formula (VII) from ACN as crystalline form D; and recrystallizing form D of the compound represented by structural formula (VII) in aqueous isopropyl alcohol (IPA) under conditions suitable for the formation of crystalline form A of the compound represented by structural formula (VII). The remaining values ​​and examples of values ​​relating to the variable elements of the process are as described above with respect to the first to sixteenth aspects of the first embodiment, the first and second aspects of the second exemplary embodiment, and the first to seventh aspects of the third exemplary embodiment. [Examples]

[0071] The compounds described in the following examples were identified and analyzed using UHPLC against standard reference compounds. Identification of heteromorphic crystal forms was confirmed and analyzed using XRPD.

[0072] Example 1. Development of a telescoping process for the synthesis of the compound represented by structural formula III. A telescoping process for synthesizing the compound represented by structural formula III from the compound of structural formula I was developed as shown in Scheme 1.

[0073] Scheme 1 [ka] Telescoping stages I and II (Scheme 1) for the synthesis of the compound represented by structural formula III are highly desirable, as they eliminate the need to isolate the compound represented by structural formula IIIa. Telescoping stages I and II enable a more efficient process with higher overall yield, shorter process time, and less handling of solvents and reagents. As described below, unintended and unexpected combinations of several reaction parameters were found, enabling the discovery of a novel and highly advantageous telescoping process.

[0074] As described below, the combination of catalyst, organic base, and ether-containing solvent unexpectedly yielded high conversion rate and stereoselectivity in Stage I of Scheme 1 (synthesis of the compound represented by structural formula IIIa). The compound represented by structural formula IIIa was subjected to hydrolysis without isolation or purification (Stage II, Scheme 1). In Stage II of Scheme 1, by using an inorganic base (e.g., KOH) as the hydrolysis reagent and IPA as the co-solvent, the compound represented by structural formula III was obtained with unexpectedly high yield and stereoselectivity.

[0075] In the disclosure process, the need to isolate the intermediate compound represented by structural formula IIIa has been eliminated.

[0076] The experiment described below demonstrates the development of the telescoping process shown in Scheme 1. The compound represented by structural formula II in R=Ph (compound II-Ph) was selected for this experiment. The synthesis scheme is shown in Scheme 2. Scheme 2 shows two isomers of the compound represented by structural formula IIIa (R=Ph). As shown in Scheme 2, the reaction between the compound represented by structural formula I and the compound represented by structural formula II-Ph results in the formation of a mixture of the compound represented by structural formula Z-IIIa-Ph and the compound represented by structural formula E-IIIa-Ph, which are cis-isomers and trans-isomers of the compound represented by structural formula IIIa, with R being phenyl. Since the desired isomer is the Z-isomer (compound represented by structural formula Z-IIIa-Ph), efforts were focused on increasing the Z / E isomer ratio while simultaneously increasing the overall conversion rate of the reaction in Stage I.

[0077] Scheme 2. [ka] 1. The effect of DABCO quantity on Stage I outcomes The following experiments demonstrated that catalytic amounts of DABCO in the presence of organic bases such as DIPEA yield the compound represented by structural formula IIIa, where R is phenyl, with high conversion rate and stereoselectivity.

[0078] The effects of reducing the DABCO stoichiometry were investigated. Using DMF as the solvent, a 2:1 stoichiometry of compounds represented by structural formula II-Ph versus those represented by structural formula I was employed. By reducing the DABCO stoichiometry from 2 to 1.1, and then to 0.1, based on the compound represented by structural formula I, the selectivity related to stage I was improved (Table 1, items 1-3). In particular, reducing the DABCO stoichiometry to 0.1 resulted in an approximately 99:1 ratio of Z-IIIa-Ph to E-IIIa-Ph.

[0079] Furthermore, by changing the stoichiometry of the reagents to 1 equivalent of the compound represented by structural formula II-Ph, 1.5 equivalents of the compound represented by structural formula I, and 1.1 equivalents of DABCO, and lowering the temperature first to 0°C to 5°C, and then to -25°C to -20°C, two notable effects were observed. First, the selectivity related to stage I increased with decreasing temperature (at 0-5°C, a ratio of 83:17 between the compound represented by structural formula Z-IIIa-Ph and the compound represented by structural formula E-IIIa-Ph was observed, and at -20-25°C, a ratio of 95:5 between the compound represented by structural formula Z-IIIa-Ph and the compound represented by structural formula E-IIIa-Ph was observed; Table 1, items 4-5). Second, the occurrence of isomerization was observed over time (Table 1, items 4-6).

[0080] When the amount of DABCO was reduced to 0.95 equivalents for both the compound represented by structural formula II-Ph and the compound represented by structural formula I, good selectivity was observed, and no isomerization over time was seen. This suggests that double bond isomerization may be related to the excess amount of free DABCO, where free DABCO is defined as unprotonated and not containing excess iodoacrylate. Further review of the experiments (e.g., items 4 and 5 in Table 1, compared to items 3 and 7) found that when the total amount of DABCO equivalents was less than 1 compared to the compound represented by structural formula II-Ph, the isomerization of the compound represented by structural formula IIIa, where R is phenyl, was slower or stopped. This finding suggested that the reaction may be less affected if DABCO is inactivated (either by binding to the iodoacrylate double bond or by being a hydroiodide salt) and not available as a free base.

[0081] It has also been demonstrated that when a catalyst (e.g., DABCO) and an organic base (e.g., DIPEA) are added to the reaction mixture, and when the total equivalent amount of the catalyst and organic base is less than 1 equivalent of the compound represented by structural formula II-Ph, the yield and selectivity of the reaction in Stage I are particularly advantageous.

[0082] A further advantage is that, under reaction conditions where catalytic amounts of DABCO are present, it was not necessary to use two equivalents of the compound represented by structural formula II-Ph to complete the reaction. It was found that just 1.2 equivalents were sufficient to achieve a conversion rate of 94% (Table 1, item 8).

[0083] [Table 1]

[0084] The above experiment demonstrates that, under certain conditions, catalytic amounts of DABCO in the presence of an organic base such as DIPEA yield a compound represented by structural formula IIIa, where R is phenyl, with high conversion rate and stereoselectivity.

[0085] 2. The effect of solvents on the results of Stage I. The study was conducted to determine the conversion rate and stereoselectivity of Stage I, as well as the effect of the solvent on telescoping stages I and II.

[0086] Since DMF is not a desirable solvent for the hydrolysis conditions in Stage II, other solvents were investigated for Stage I. The experiments described below showed that MeTHF is a favorable solvent for Stage I, providing high conversion rates and selectivity.

[0087] The effect of solvent polarity on the Stage I reaction was tested. A decrease in solvent polarity (from DMF to toluene or MeTHF) resulted in an improvement in the ratio of the compound represented by structural formula Z-IIIa-Ph to the compound represented by structural formula E-IIIa-Ph (from approximately 80:20 for DMF to a high 95:5 for MeTHF, as shown in item 8 of Table 1 (see Table 2)). As the solvent polarity decreased, both the desired reaction rate and isomerization rate decreased. Compared to toluene, MeTHF provided higher selectivity and comparable activity (Table 2, items 2-4). Due to the high conversion rate and selectivity of the Stage I process when using MeTHF and carrying out this reaction at room temperature, the possibility of using this solvent as a carrier in a telescoping process to link the Stage I process to the subsequent hydrolysis step in Stage II was suggested.

[0088] [Table 2]

[0089] Using MeTHF as a solvent in Stage I results in a high conversion rate and selectivity for the compound represented by structural formula IIIa. As a result, opportunities for telescoping in Stages I and II are provided, thus avoiding the step of isolating the compound represented by structural formula IIIa and the associated material loss.

[0090] 3. Effects of metal hydroxides and co-solvents in Stage II. Referencing Scheme 3, Stage II, experiments were conducted to determine different combinations of inorganic bases and solvents. When used as a hydrolysis reagent, IPA was found to yield the compound of structural formula III with favorable yield and stereoselectivity when used with inorganic bases such as NaOH and KOH, and when used as a co-solvent with MeTHF and water.

[0091] Scheme 3. [ka] Lithium hydroxide was initially selected as the hydrolysis reagent because its reaction kinetics are favorable and it is frequently used in ester hydrolysis processes. Hydrolysis of the compound represented by structural formula IIIa-iPr by lithium hydroxide (5 equivalents) in MeTHF is relatively slow in the absence of IPA or other phase transfer agents (Table 3, items 1-4). This process also involves significant isomerization, resulting in the formation of an undesirable compound represented by structural formula E-III.

[0092] Furthermore, LiOH is not a preferred reagent for pharmaceutical applications. Since Li salts are pharmaceutically effective compounds themselves, the Li levels in pharmaceutical intermediates and final products generated using LiOH must be carefully monitored. Therefore, NaOH and KOH were tested as alternatives to LiOH (Table 3, items 5-12, 17-24).

[0093] IPA was tested as a co-solvent due to its ability to promote reactions between the organic and aqueous phases by imparting partial miscibility. The presence of IPA as a co-solvent significantly improved the results of the hydrolysis process (Table 3, items 13-24).

[0094] [Table 3]

[0095] In this experiment, the Stage I reaction was carried out under the following conditions: The compound represented by structural formula I (12 g) and DABCO (0.1 equivalent, 0.48 g) were dissolved in MeTHF, and then the compound represented by structural formula II-iPr (1.2 equivalent, 12.3 g) and DIPEA (1.0 equivalent, 7.4 mL) were added. The reaction mixture was stirred for 20 hours, and then washed with 5 volume equivalents of water (relative to the volume of the compound represented by structural formula I). Aliquots (1 / 6 of the reaction mixture) were taken and treated with reagents according to the hydrolysis conditions in Table 3.

[0096] The data in Table 3 shows that, compared to LiOH, both NaOH and KOH improved the hydrolysis rate of the compound represented by structural formula IIIa-iPr while maintaining a low Z / E isomerization level. Furthermore, the data in Table 3 shows that IPA improved both the conversion rate and stereoselectivity related to stage II of scheme 3.

[0097] Example 2. Synthesis of the compound represented by structural formula III. The following examples disclose the synthesis of the compound represented by structural formula III on a 1.0 kg scale. The compound represented by structural formula III is synthesized with a purity of over 99% (UPLC) and a yield of 72-75%. Under a nitrogen atmosphere, 1,000 kg of the compound represented by structural formula I (1 equivalent), 40 g of DABCO (0.1 equivalent), and 2,559 kg of MeTHF were charged into a 50 L glass reactor, and the mixture was stirred to dissolve it. • To this mixture, 1,040 kg of the compound represented by structural formula II (where R is an isopropyl group (1.2 equivalents)) was added, and the funnel was rinsed with 0.853 kg of MeTHF. • 460 g of DIPEA (1.0 equivalent) was added to this mixture using a dropping funnel, and the funnel was rinsed with 0.853 kg of MeTHF. The mixture was stirred at 20-25°C for 16 hours, and then sampled to confirm the completion of the reaction. • 5.0 kg of DD water was added to this container while gently stirring and maintaining the temperature at 20-25°C, and the resulting mixture was stirred for 20 minutes. The stirring was stopped, and the layers were separated. The lower aqueous layer was removed and discarded. To the upper organic layer, 30 g of 37% HCl solution in 2,975 kg of water was added, followed by 1.18 kg of brine, while gently stirring and maintaining the temperature at 20-25°C. The mixture was stirred at 20-25°C for 20 minutes, then the stirring was stopped and the layers were separated. The lower aqueous phase was removed and discarded. • 1.57 kg of IPA was added to this container while gently stirring at 20-25°C. To this reaction mixture, a solution of 1,174 kg (5 equivalents) of KOH in 5.0 kg of DD water was added while gently stirring and maintaining the temperature at 20-25°C. The mixture was stirred at 20-25°C for 3 hours, and then sampled to confirm the completion of the reaction. Once the reaction was complete, 5,935 kg of brine was added to the mixture while gently stirring. This batch was vigorously stirred at 20-25°C for 20 minutes. Then, stirring was stopped and the layers were separated. The lower aqueous layer was separated and discarded. 1,998 kg of DD water was added to the organic layer while stirring vigorously, and then stirred for 20 minutes. While vigorously stirring, the pH of the mixture (lower phase) was adjusted to a target of 0-2 with 0.934 kg of 5 M HCl solution (aq.). The batch temperature was gently raised to 50-55°C while stirring, and the stirring was maintained for 20 minutes. While maintaining the temperature at 50-55°C, the aqueous layer at the bottom was separated and discarded. The retained organic phase was cooled to 0-5°C and then distilled to a target volume of 3 L. After distillation was complete, the batch temperature was raised to 50-55°C and held at that temperature for 1 hour. While maintaining a temperature of 50-55°C and gently stirring, 5,645 kg of isooctane was added to the container over a minimum of 30 minutes. Following the addition of isooctane, the temperature was adjusted to 20-25°C over a minimum of 60 minutes, and then maintained at 20-25°C for a minimum of 1 hour. The batch was cooled to 0-5°C over a minimum of 1 hour, and then held at that temperature for at least 1 hour. The batch was filtered, and the filter cake was washed with 2,145 kg of isooctane at 0-5°C. The filtered product was dried on the filter under a nitrogen stream until it was dry. The yield of the compound represented by structural formula III was 72-75%, and the purity was over 99% (UPLC).

[0098] Example 3. Synthesis of the compound represented by structural formula III. The following examples disclose the synthesis of the compound represented by structural formula III on a 100 kg scale. The compound represented by structural formula III is synthesized with a purity of over 99.7% (UPLC) and a yield of 75 ± 10%. In contrast to Example 2, in which the solid content of the compound represented by structural formula III precipitates with isooctane, in this example, the solid content of the compound represented by structural formula III precipitates with heptane. In a clean, inert glass-lined reactor with a capacity of 4000 L, one equivalent of the compound with structural formula I, 0.1 equivalents of DABCO, and MeTHF were charged. Under a nitrogen atmosphere, the resulting mixture was stirred and dissolved at 15 / 20°C for at least 15 minutes. The temperature of the mixture was adjusted to 10 / 20°C, and the compound represented by structural formula II (where R is an isopropyl group (1.2 equivalents)) was added. Next, the MeTHF rinse was added to the mixture. DIPEA (1.0 equivalent) was added to this mixture at 10 / 20°C (target temperature of 10°C), followed by the addition of the MeTHF rinse at 10 / 20°C. The resulting reaction mixture was stirred at 15°C for at least 12 hours, adjusting the stirring speed to maintain vigorous stirring of the mixture. The reaction mixture was kept at 15°C for at least 2 hours with stirring. Water was added to the reaction mixture while maintaining a mixture temperature of 10 / 25°C. The mixture was stirred at 15 / 20°C for at least 15 minutes to separate, and the lower first aqueous phase was removed. The remaining organic phase was transferred to a new, dry, inert 6000L glass-lined reactor, followed by the transfer of the MeTHF rinse. In a clean, inert glass-lined reactor, a deactivation solution was prepared by charging water, sodium chloride, and hydrochloric acid, and the mixture was stirred at 15 / 25°C for at least 30 minutes until dissolved. The prepared deactivation solution was added to a second reactor (6000L reactor) containing the organic phase, and mixed for at least 15 minutes at a mixture temperature of 15 / 20°C (with little or no exothermic reaction). The mixture was allowed to stand for at least another 15 minutes at 15 / 20°C to separate the aqueous and organic layers. The aqueous phase was removed, leaving the interfacial phase, if present, along with the organic phase. The reactor was rinsed with water, dried, and then water and KOH were added and mixed at 15 / 25°C for at least 30 minutes. IPA was added to the organic phase in a 6000L reactor, and the mixture was stirred for 5-10 minutes at 15 / 25°C. At 15°C, the water / KOH solution from the third reactor was added to the organic phase while maintaining the temperature of the second reactor at 15 / 25°C (the addition was exothermic), thereby generating a reaction mixture. Next, the reaction mixture in a 6000 L glass-lined reactor was stirred at 20 / 25°C under a nitrogen atmosphere for at least 2 hours, and then sampled. If unsuitable, the reactor was continued stirring at 20 / 25°C under a nitrogen atmosphere for at least another 2 hours to form the compound represented by structural formula III. If suitable, the reaction was deactivated. In a separate reactor, water and sodium chloride were added and stirred at 15 / 25°C for at least 30 minutes until dissolved. The sodium chloride solution was added to the reaction mixture and vigorously stirred at 15 / 25°C for at least 15 minutes, and then allowed to stand for at least 15 minutes. The aqueous phase was removed, leaving the interfacial phase and organic phase, if present. The reactor was rinsed with water, dried, and then charged with water and HCl, and mixed at 20 / 25°C for at least 10 minutes. Water was added to the organic phase in a 6000L reactor at 15 / 25°C, held for 5-10 minutes without stirring, and the total volume was recorded. • Restart stirring, add the required amount of HCl solution to achieve the target pH of 0.5–2.0, and mix at 15 / 25°C for at least 10 minutes. The mixture was heated at 50 / 55°C until the compound represented by structural formula III was solubilized, stirred for 10 minutes, and then allowed to stand for at least 15 minutes (bulk temperature 50 / 55°C). The aqueous phase was removed, leaving the interface phase along with the organic layer, and discarded. The organic phase was cooled to 30 / 40°C under reduced pressure and concentrated to approximately 3 volume equivalents. After the concentration process was complete, the final organic phase was heated to 50 / 55°C. Over a period of more than one hour, 99% heptane was added to the final organic phase in a second reactor with an internal temperature of 50 / 55°C. The mixture was cooled to 0 / 5°C over at least 3 hours, and then stirred at that temperature for at least 1.5 hours. A cake rinse was prepared by combining MeTHF and 99% heptane. The slurry was centrifuged to form a series of equivalent cakes, and each cake was washed with a MeTHF / heptane mixture. The compound represented by structural formula III was transferred to a stirring dryer and dried under reduced pressure until the product was dry and exhibited a homogeneous appearance. The compound represented by structural formula III was obtained in 75±10% yield, with a Z / E ratio of >99:1 and a purity of >99.7%.

[0099] Example 4: Synthesis of the compound represented by structural formula (I) Synthesis scheme 3 [ka] Compound (IV) and 99% (4.2 wts) acetic acid were charged into a clean, inert glass-lined reactor under a nitrogen atmosphere with a head gap, and the mixture was maintained at 25 / 35°C or below with stirring until compound (IV) dissolved.

[0100] The bulk temperature was adjusted to 20 / 25°C, and then 1.4 molar equivalents of hydrazine monohydrate (compound (V)) stock solution (0.225 wts) were charged into the container (exothermally) for 90 minutes using NMT while maintaining a temperature of 20 / 30°C.

[0101] Once the addition was complete, the batch temperature was raised to 55°C and the mixture was stirred for at least 5-16 hours (80 rpm) until the reaction was complete (determined by UHPLC).

[0102] Once it was confirmed that the reaction was complete, crystallization was induced by slowly and uniformly adding demineralized water or purified water (hereinafter referred to as "water") (5 wts) to the mixture over a minimum of 2.5 hours, while maintaining the internal temperature at 55°C with stirring.

[0103] An additional 5 wts of water was added to the mixture over a minimum of 1 hour at a temperature range setpoint of 55°C.

[0104] The mixture was stirred at 55°C for at least 30 minutes. After confirming nucleation, crystallization was allowed to proceed, and the mixture was slowly cooled to 20 / 25°C over a minimum of 3 hours, during which time it was stirred at 20 / 25°C for at least 1 hour.

[0105] The compound (I) product was isolated by centrifugation, washed with water (12 wts), transferred to a stirring dryer, and dried under reduced pressure until dry and homogeneous. Drying was continued until the water content and solvent content met the specifications.

[0106] The dried product is cooled to ≤30°C and packaged.

[0107] Example 5: Synthesis of compound form D represented by structural formula (VII) Synthesis scheme 5 [ka] Compound (III), compound (VI) (0.335 wts ± 2%), and MeTHF (5.8 wts) were charged into a 4000 L dry, inert glass-lined reactor, and the mixture was stirred for 15 minutes at NLT, 15 / 20°C, under a nitrogen atmosphere.

[0108] The mixture was cooled to -20 / -25°C. Then, DIPEA (0.846 wts ± 2%) was added to the mixture with MeTHF rinse (0.26 wts) while maintaining the temperature between -20 / -25°C (exothermic).

[0109] A commercially available 50% propylphosphonic anhydride (T3P®) solution (1.22 wts ± 2% based on T3P® stock solution) was slowly added to the mixture over NLT for 6 hours at a temperature of -20°C NMT, followed by rinsing with MeTHF (0.86 wts). The mixture was stirred under a nitrogen atmosphere for 30 minutes at NLT between -20 / -25°C, and then the temperature of the mixture was rapidly adjusted to 10 / 15°C while stirring. Once the temperature was reached, a sample was taken to monitor the reaction (UHPLC using known standards).

[0110] If the reaction was deemed suitable by UHPLC, the solution was diluted with MeTHF (0.43 wts) and inactivated with purified water (5 volumes) at 10 / 15°C with stirring.

[0111] The two-phase mixture was stirred at NLT, 15 / 25°C for 15 minutes, then the layers were allowed to stand at 15 / 25°C for at least 30 minutes, after which the aqueous layer (bottom) was removed.

[0112] The interfacial and organic layers, if present, were washed with water (4.7 vol) and sodium chloride (0.3 wts) while vigorously stirring at NLT, 15 / 25°C for 25 minutes.

[0113] The mixture was allowed to stand for 30 minutes at NLT, 15 / 25°C, after which the aqueous layer (bottom) and any interfacial phase were removed. The remaining organic phase was slowly stirred at NMT, 15 / 25°C for 5 minutes, then allowed to stand at NLT for 15 minutes, and any additional settled aqueous phase was removed.

[0114] The organic layer was placed under reduced pressure, and the mixture was heated to 35 / 45°C with a jacket temperature of 55°C NMT. ​​The mixture was concentrated at 20 / 45°C until a residual volume of 5 volumes was reached.

[0115] Once the concentration process was complete, the mixture was cooled to 20 / 25°C.

[0116] The organic mixture was filtered and transferred to a concentration container with MeTHF rinse (0.43 wts).

[0117] The MeTHF solution was heated to 35 / 45°C with a 55°C NMT jacket temperature, and filtered ACN (7.8 wts) was added. During concentration, solvent replacement was carried out by distillation while maintaining the temperature of the mixture at 20 / 45°C with a 55°C NMT jacket temperature until it reached approximately 10 volumes.

[0118] Filtered ACN (3.9 wts) was added to the organic concentrate and held at 20 / 45°C for 15 minutes under NLT conditions. The mixture was concentrated at 20 / 45°C under reduced pressure and jacketed at a temperature of 55°C NMT until it reached approximately 10 volumes.

[0119] The filtered ACN (3.9 wts) was added repeatedly, the mixture was concentrated to 10 volumes, and then filtered ACN (3.9 wts) was added, and the mixture was stirred for 15 minutes at NLT, 20 / 45°C.

[0120] Once the MeTHF content met the specifications (determined by GC), the organic mixture was heated to 65±2°C with a 75°C NMT jacket temperature and held for 15 / 30 minutes.

[0121] The organic mixture was transferred to a crystallization vessel with an ACN (16 kg) rinse. The temperature of the mixture was adjusted to 65 ± 2°C if necessary and held for 15 / 30 minutes.

[0122] The mixture was cooled to 20 / 25°C over NLT for 3 hours, stirred at 20 / 25°C for 1-2 hours, and then further cooled to 0 / 5°C over NLT for 3 hours while stirring. The mixture was then held at 0 / 5°C under NLT for 1 hour.

[0123] The crystallized mixture was centrifuged to form a series of equivalent cakes (maximum cake size for a 30 kg wet cake), and each cake was washed with chilled, filtered ACN (141 kg / 180 L). 141 kg / 180 L of cake washing solution was equivalent to 10 volumes of NLT of ACN (if the cake weighed 30 kg or less).

[0124] The mother liquor and washing solution were removed. After gentle stirring at atmospheric pressure and ambient temperature for 4-6 hours, the filter cake was dried under reduced pressure (jacket temperature of 45°C NMT) until the product was dry and exhibited a homogeneous appearance. The process was considered complete when the criteria for drying loss were met.

[0125] Example 6: Conversion of crystalline heteromorphic forms of the compound represented by structural formula (VII); preparation of form A Forms D and A as referred to herein are the same forms A and D as described in their entirety in U.S. Patent No. 10,519,139, which is incorporated herein by reference.

[0126] Synthesis scheme 6 [ka] Compound (VII) form D was charged into a 4000 L dry, inert glass-lined reactor along with filtered IPA (2.4 wts) and stirred. Purified water (3 wts) was added to the mixture.

[0127] The temperature was increased, and then maintained at 40±2℃ for at least 5 hours and no more than 12 hours to induce heteromorphic transformation from morph D to morph A.

[0128] Next, the slurry was cooled to 15 / 20°C over at least 1 hour, and purified water (10 wts) was added while stirring at 15 / 20°C.

[0129] The mixture was then rinsed with water (200 L) and transferred to a 6000 L dry, inert glass-lined reactor, where the temperature was maintained at 15 / 20°C while stirring for at least 1 hour.

[0130] In a separate reactor, filtered IPA (0.79 wts) and water (4 wts) were added and stirred for at least 10 minutes. The solvent mixture was then transferred to a clean, dedicated container for washing the cake.

[0131] The minimum number of centrifugation cakes was calculated, ensuring that the size of each cake was less than or equal to 40 kg of wet cake. This slurry was then centrifuged into approximately equivalent cakes, each weighing less than 40 kg.

[0132] Each of the centrifugal cakes was washed with a fixed volume of IPA / aqueous solution (150 L), and then removed from the centrifuge.

[0133] The mother liquor and washing solution were recovered. A portion of the mother liquor could be used to rinse the remaining residue in the centrifuge as needed. The filter cake was pooled and dried under reduced pressure (maximum jacket temperature of 45°C) until the product was dry and had a homogeneous appearance.

[0134] All patents, published applications, and related teachings relating to the documents cited herein are incorporated in their entirety by reference.

[0135] While the present invention has been specifically shown and described with reference to its exemplary embodiments, those skilled in the art will understand that various modifications can be made in form and detail without departing from the scope of the invention as encompassed in the appended claims.

[0136] The following are examples of aspects of the present invention. Item 1 Compounds represented by structural formula III [ka] The process of forming: Compound represented by structural formula (I) and compound represented by structural formula (II) [ka] The compound represented by structural formula (IIIa) is obtained in the presence of a catalyst, an organic base, and an ether-containing solvent. [ka] A step of reacting under conditions suitable for the production of; and A step of reacting the compound represented by structural formula (IIIa) with an inorganic base in the presence of isopropyl alcohol (IPA) under conditions suitable for the formation of the compound represented by structural formula (III), without isolation; and The step includes isolating the compound represented by the above structural formula (III), Here, R is C2-C5 alkyl, C6-C 18 Aryl, 5-18 member heteroaryl, C3-C 12 A process comprising a cycloalkyl or 3- to 12-membered heterocycloalkyl, each of which is optionally and independently substituted with one or more substituents selected from halo, CN, OH, C1-C3 alkyl, C1-C3 haloalkyl, -NO2, -NH2, -NH(C1-C3 alkyl), -N(C1-C3 alkyl)2, and C1-C3 alkoxy. Section 2 R is C2-C5 alkyl or C6-C 18 The process described in item 1, which is an aryl. Section 3 The process described in item 1 or 2, wherein R is a C2-C5 alkyl group. Section 4 The process according to any one of items 1 to 3, wherein R is isopropyl. Section 5 The process according to item 1 or 2, wherein R is phenyl. Item 6 The process according to any one of items 1 to 5, wherein the catalyst and the organic base are present in a combined total amount less than 1 molar equivalent of the compound represented by the structural formula II. Item 7 The process according to any one of items 1 to 6, wherein the catalyst is present in an amount of 0.05 to 0.2 molar equivalents based on the amount of the compound represented by the structural formula I. Item 8 The process according to any one of items 1 to 7, wherein the catalyst is present in an amount of 0.1 molar equivalents based on the amount of the compound represented by the structural formula I. Item 9 The process according to any one of items 1 to 8, wherein the catalyst is selected from the group consisting of 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-diazabicyclo[4.3.0]non-5-ene, and 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene. Item 10 The process according to any one of items 1 to 9, wherein the catalyst is DABCO. Item 11 The process according to any one of items 1 to 10, wherein the organic base is present in an amount of 0.5 to 2 molar equivalents based on the amount of the compound represented by the structural formula I. Item 12 The process according to any one of items 1 to 11, wherein the organic base is present in an amount of 1.0 molar equivalents based on the amount of the compound represented by the structural formula I. Item 13 The process according to any one of items 1 to 12, wherein the organic base is selected from the group consisting of DIPEA, Et3N, piperidine, pyridine, and 4-(dimethylamino)pyridine. Item 14 The process according to any one of items 1 to 13, wherein the organic base is DIPEA. Item 15 The ether-containing solvent is selected from the group consisting of MeTHF, CPME, and MTBE, and the process according to any one of claims 1 to 14. Claim 16 The ether-containing solvent is MeTHF, and the process according to any one of claims 1 to 15. Claim 17 The amount of the compound of Structural Formula II is 1.0 to 1.5 molar equivalents based on the amount of the compound of Structural Formula I, and the process according to any one of claims 1 to 16. Claim 18 The inorganic base is LiOH, NaOH, or KOH, and the process according to any one of claims 1 to 17. Claim 19 The inorganic base is KOH or NaOH, and the process according to any one of claims 1 to 18. Claim 20 The inorganic base is KOH, and the process according to any one of claims 1 to 19. Claim 21 The suitable conditions for the formation of the compound represented by Structural Formula IIIa include reacting the compound represented by Structural Formula I and the compound represented by Structural Formula II at a temperature of 5°C to 55°C, and the process according to any one of claims 1 to 20. Claim 22 The suitable conditions for the formation of the compound represented by Structural Formula IIIa include reacting the compound represented by Structural Formula I and the compound represented by Structural Formula II for a period of 5 hours to 30 hours, and the process according to any one of claims 1 to 21. Claim 23 The suitable conditions for the formation of the compound represented by Structural Formula III include reacting the compound represented by Structural Formula IIIa and an inorganic base at a temperature of 5°C to 55°C, and the process according to any one of claims 1 to 22. Claim 24 The suitable conditions for the formation of the compound represented by Structural Formula III include reacting the compound represented by Structural Formula IIIa and an inorganic base for a period of 1 hour to 10 hours, and the process according to any one of claims 1 to 23. Section 25 The process according to any one of claims 1 to 24, further comprising the step of isolating the compound represented by structural formula III from the reaction mixture. Section 26 The step of isolating the compound represented by structural formula III is: (i) Add water and HCl to the reaction mixture containing the compound represented by structural formula III, thereby generating an aqueous phase and an organic phase; (ii) Separating the organic phase and optionally concentrating it to produce a final organic phase; (iii) C5~C 12 The steps include adding a hydrocarbon solvent to the final organic phase to generate a precipitate of the compound represented by structural formula III, and (iv) The step of isolating the precipitate of the compound represented by structural formula III. The process described in Section 25, including the process described in Section 25. Section 27 Said C5~C 12 The hydrocarbon solvent is heptane, as described in item 26. Section 28 Said C5~C 12 The hydrocarbon solvent is isooctane, as described in Section 26. Section 29 Compounds represented by structural formula (IV) [ka] And, hydrazine represented by structural formula (V) H2NNH2(V) and are compounds represented by structural formula (I) [ka] The step of reacting under the conditions suitable for the production of; and Steps to isolate the compound represented by the above structural formula (I) The processes described in any one of paragraphs 1 to 28, further including the processes described in any one of paragraphs 1 to 28. Item 30 The step of reacting the compound represented by the structural formula (IV) with the hydrazine represented by the structural formula (V) is carried out in the presence of an organic acid, and the process according to item 29. Item 31 The organic acid is formic acid, acetic acid or propionic acid, and the process according to item 30. Item 32 The organic acid is acetic acid, and the process according to item 31. Item 33 The suitable conditions for the production of the compound represented by the structural formula (I) include the step of reacting the compound represented by the structural formula (IV) with the hydrazine represented by the structural formula (V) at a temperature of 50°C to 60°C, and the process according to any one of items 29 to 32. Item 34 Compound represented by structural formula (III)

Chemical formula

Chemical formula

Chemical formula

Claims

1. Compound represented by structural formula VII 【Chemistry 1】 The process of manufacturing: - The compound represented by structural formula I, 【Chemistry 2】 Compounds represented by structural formula II 【Transformation 3】 Using 1,4-diazabicyclo[2.2.2]octane (DABCO) as a catalyst, Et ３ The compound represented by structural formula IIIa is obtained by reacting N, an organic base selected from diisopropylethylamine (DIPEA), piperidine, pyridine, and 4-dimethylaminopyridine (DMAP), and the solvent 2-methyltetrahydrofuran (MeTHF). 【Chemistry 4】 The step of generating, where R is C ２ ~C ５ Alkyl or C ６ ~C １８ It is an aryl compound, and furthermore, DABCO is present in an amount of 0.05 to 0.2 molar equivalents based on the amount of the compound represented by structural formula I; - A step of reacting the compound represented by structural formula IIIa with an inorganic base in the presence of isopropyl alcohol (IPA) without isolation to produce the compound represented by structural formula III, where the inorganic base is LiOH, NaOH, or KOH; - Compound represented by the above structural formula III 【Transformation 5】 The steps of isolating, and - Compounds represented by structural formula III 【Transformation 6】 And, hydrazine represented by structural formula VI 【Transformation 7】 The step involves reacting the two in the presence of a polar solvent, a second organic base, and a coupling agent to produce the compound represented by structural formula VII. A process that includes this.

2. - A step of replacing the polar solvent with acetonitrile (ACN); - A step of crystallizing the compound represented by the structural formula VII from the ACN as crystalline form D, wherein form D is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 3.7°, 7.3°, 10.9°, 18.3°, and 21.9°. The process according to claim 1, further comprising:

3. The compound represented by the above structural formula VII 【Transformation 8】 The process according to claim 1 or 2, further comprising the step of recrystallizing morphology D in aqueous isopropyl alcohol (IPA) to produce crystalline morphology A of the compound represented by structural formula VII, wherein morphology A is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 4.4°, 19.9°, 21.3°, and 22.0°.

4. The process according to any one of claims 1 to 3, wherein R is isopropyl or phenyl.

5. The process according to any one of claims 1 to 4, wherein the catalyst and the organic base are present in a combined amount of less than one molar equivalent of the compound represented by structural formula II.

6. The process according to any one of claims 1 to 4, wherein the catalyst is present in an amount of 0.1 molar equivalents based on the amount of the compound represented by structural formula I.

7. The process according to any one of claims 1 to 4, wherein the organic base is present in an amount of 0.5 to 2 molar equivalents based on the amount of the compound represented by structural formula I.

8. The process according to any one of claims 1 to 4, wherein the organic base is present in an amount of 1.0 molar equivalent based on the amount of the compound represented by structural formula I.

9. The aforementioned organic bases are DIPEA, Et ３ The process according to any one of claims 1 to 8, selected from the group consisting of N, piperidine, pyridine, and 4-(dimethylamino)pyridine.

10. The process according to any one of claims 1 to 9, wherein the amount of the compound of structural formula II is 1.0 to 1.5 molar equivalents based on the amount of the compound of structural formula I.

11. The process according to any one of claims 1 to 10, wherein the step of reacting a compound represented by structural formula I with a compound represented by structural formula II to produce a compound represented by structural formula IIIa includes the step of reacting the compound represented by structural formula I with the compound represented by structural formula II at a temperature of 5°C to 55°C.

12. The process according to any one of claims 1 to 11, wherein the step of reacting a compound represented by structural formula IIIa with an inorganic base to produce a compound represented by structural formula III includes the step of reacting the compound represented by structural formula IIIa with an inorganic base at a temperature of 5°C to 55°C.

13. The step of isolating the compound represented by the aforementioned structural formula III is: (i) Add water and HCl to the reaction mixture containing the compound represented by structural formula III, thereby generating an aqueous phase and an organic phase; (ii) Separating the organic phase and optionally concentrating it to produce a final organic phase; (iii) C ５ ~C １２ The steps include adding a hydrocarbon solvent to the final organic phase to generate a precipitate of the compound represented by structural formula III, and (iv) The step of isolating the precipitate of the compound represented by structural formula III. The process according to claim 12, including the process described in claim 12.

14. Said C ５ to C １２ The hydrocarbon solvent is heptane or isooctane, the process according to claim 12.

15. - Compound represented by structural formula IV 【Chemistry 9】 And, hydrazine represented by structural formula V H ２ NNH ２ V The compound represented by structural formula I is obtained by reacting these two substances. 【Chemistry 10】 Steps to generate The process according to any one of claims 1 to 14, further comprising:

16. The process according to any one of claims 1 to 15, wherein the step of reacting the compound represented by structural formula IV with the hydrazine represented by structural formula V is carried out in the presence of an organic acid selected from formic acid, acetic acid, or propionic acid.

17. The process according to claim 16, wherein the organic acid is acetic acid.

18. The compound represented by the aforementioned structural formula I. 【Chemistry 11】 The process for producing the compound is the process according to any one of claims 1 to 17, comprising the step of reacting the compound represented by structural formula IV with the hydrazine represented by structural formula V at a temperature of 50°C to 60°C.

19. The second organic base is DIPEA, Et ３ The process according to any one of claims 1 to 18, selected from the group consisting of N, piperidine, pyridine, and 4-(dimethylamino)pyridine.

20. The process according to claim 19, wherein the second organic base is DIPEA.

21. The aforementioned polar solvent is C １ ~C ６ A process according to any one of claims 1 to 20, selected from the group consisting of alcohol, MeTHF, CPME, and MTBE.

22. The process according to claim 21, wherein the polar solvent is MeTHF.

23. The process according to any one of claims 1 to 22, wherein the coupling agent is selected from the group consisting of propylphosphonic anhydride (T3P) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).

24. The process according to claim 23, wherein the coupling agent is T3P.

25. The process according to any one of claims 1 to 24, wherein the production of the compound represented by structural formula VII comprises the step of reacting the compound represented by structural formula III with the hydrazine represented by structural formula VI at a temperature of -25°C to -15°C.

26. The formation of form A of the compound represented by the above structural formula VII is as follows: The steps of: dissolving form D in the aqueous IPA to produce a slurry; and The step of holding the slurry at a temperature of 38°C to 42°C for 5 to 12 hours. The process according to any one of claims 3 to 25, including the process described in any one of claims 3 to 25.

Images